NeurAxon Inc has secured US$32 million in series B financing for further development of its pain therapeutics targeting neuronal nitric oxide synthase (nNOS) for the treatment of neuropathic pain and migraines. Created in 2004, the Toronto-based firm is opening its US headquarters in Waltham MA this fall. Leading the latest financing is Delphi Ventures and OrbiMed Advisors LLC with participation by BDC Venture Capital, Genesys Capital Partners, HIG Ventures, NeuroVentures Fund, Ventures West Capital Ltd and NeurAxon CEO Lawrence Bloch.…